Skip to main content
Log in

L-DOPA infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine

  • Full Papers
  • Published:
Journal of Neural Transmission / General Section JNT Aims and scope Submit manuscript

Summary

In the present experiment we tested the effects of L-DOPA upon dopamine (DA) efflux in vitro from superfused corpus striatal tissue fragments in medium containing reserpine. The purposes of this experiment were first, to evaluate the effects of differing infusion modes of L-DOPA upon DA efflux under conditions in which DA storage capacity has been diminished, and second, to compare this L-DOPA stimulated DA efflux with that of other putative DA secretagogues such as amphetamine and postassium. No differences were obtained in stimulated DA efflux between superfusions performed in the presence or absence of reserpine (10 μM) in the medium when L-DOPA (5 μM) was infused in a continuous (70 minute) mode during the superfusion. In contrast, a continuous infusion of either amphetamine (10 μM) or high potassium (30 mM) resulted in significantly greater stimulated DA efflux in superfusions performed with reserpine in the medium. In addition, when L-DOPA (5 μM) was administered for a brief 10-minute infusion period, a significantly greater stimulated DA efflux was obtained with superfusions containing reserpine in the medium. These results suggest that the mode of L-DOPA infusion may be an important factor in regulating DA release under conditions of diminished DA storage capacity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Bennett JP, Turk M, Landow E (1989) Continuous oral administration of L-dihydroxyphenylalanine (L-DOPA) solution to patients with advanced Parkinson's disease. Clin Neuropharmacol 12: 285–292

    Google Scholar 

  • Brannan T, Bhardwaj A, Martinez-Tria J, Weinberger J, Yahr M (1990) Striatal L-DOPA metabolism studied in vivo in rats with nigrostriatal lesions. J Neural Transm [P-D Sect] 2: 15–22

    Google Scholar 

  • Callaway CW, Kuczenski R, Segal DS (1989) Reserpine enhances amphetamine stereotypes without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res 505: 83–90

    Google Scholar 

  • Chase TN, Baronti F, Fabbrine G, Heuser IJ, Juncos JL, Mouradian MM (1989) Rationale for continuous dopaminergic therapy of Parkinson's disease. Neurology 39 [Suppl 2]: 7–10

    Google Scholar 

  • Dluzen DE, Ramirez VD (1987) In vivo release of dopamine and its metabolites following a direct infusion of L-DOPA into the caudate nucleus of awake, freely behaving rats using a push-pull cannula. Neurosci Lett 82: 29–34

    Google Scholar 

  • Dluzen DE, Ramirez VD (1989) Progesterone enhances L-DOPA-stimulated dopamine release from the caudate nucleus of freely behaving ovariectomized-estrogen primed rats. Brain Res 494: 122–128

    Google Scholar 

  • Dluzen DE, McDermott JL (1991 a) The effect of long-term treatment with deprenyl on basal and L-DOPA evoked dopamine release from the corpus striatum of aged rats. J Neural Transm [Gen Sect] 85: 145–156

    Google Scholar 

  • Dluzen DE, McDermott JL (1991 b) Striatal dopamine release in vitro from immature male rats shows enhanced responsiveness to pulsatile, but not continuous, infusions of L- DOPA. Dev Brain Res 62: 273–276

    Google Scholar 

  • Dluzen DE, McDermott JL, Ramirez VD (1991) Changes in dopamine release in vitro from the corpus striatum of young versus aged rats as a function of infusion modes of L-DOPA, potassium and amphetamine. Exp Neurol 112: 153–160

    Google Scholar 

  • Duvoisin R (1987) History of parkinsonism. Pharmacol Ther 32: 1–17

    Google Scholar 

  • Elverfors A, Nissbrandt H (1991) Reserpine-insensitive dopamine release in the substantia nigra. Brain Res 557: 5–12

    Google Scholar 

  • Enber TM, Susel Z, Juncos JL, Chase TN (1989) Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 16: 291–298

    Google Scholar 

  • German DC, McMillen BA, Sanghera MK, Saffer ST, Shore PA (1981) Effect of severe dopamine depletion on dopamine neuronal impulse flow and on tyrosine hydroxylase regulation. Brain Res Bull 6: 131–134

    Google Scholar 

  • Juncos JL, Engber TM, Raisman R, Thirbout F, Ploska A, Agid Y, Chase TN (1989) Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 25: 473–478

    Google Scholar 

  • Kittner B, Brautigam M, Hesken H (1987) PC 12 cells: a model system for studying drug effects of dopamine synthesis and release. Arch Int Pharmacodyn 286: 181–194

    Google Scholar 

  • Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmais C, Jones T, Marsden CD (1986) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 49: 853–860

    Google Scholar 

  • Lieberman A (1988) Dopamine agonists: new perspectives. Neuro View 4: 1–20

    Google Scholar 

  • Marsden CD (1980) “On-off” phenomenon in Parkinson's disease. In: Rinne UK, et al (eds) Parkinson's disease: current progress, problems in management. Elsevier, Amsterdam, pp 241–254

    Google Scholar 

  • Melamed E (1987) The failing efficacy of long term levodopa therapy in Parkinson's disease. I. Chemical features and neurochemical mechanisms. Neuro View 3: 1–16

    Google Scholar 

  • Melamed E (1990) Interactions of exogenous L-DOPA with nigrostriatal dopaminergic neurons in Parkinson's disease. In: Streigler MB, et al (eds) Parkinson's disease: anatomy, pathology and therapy. Raven Press, New York, pp 61–66 (Adv Neurol 53)

    Google Scholar 

  • Mouradian MM, Heuser IJE, Baronti F, Chase TN (1990) Modification of central do- paminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 27: 18–23

    Google Scholar 

  • Niddam R, Arbilla S, Scatton B, Dennis T, Langer SZ (1985) Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine. Naunyn-Schmiedebergs Arch Pharmacol 329: 123–127

    Google Scholar 

  • Ofori S, Bretton C, Hof P, Schorderet M (1986) Investigation of dopamine content, synthesis, and release in the rabbit retina in vitro. I. Effects of dopamine precursors, reserpine, amphetamine, and L-DOPA decarboxylase and monoamine oxidase inhibitors. J Neurochem 47: 1199–1206

    Google Scholar 

  • Ramirez VD (1983) Hormones and striatal dopaminergic activity: a novel neuroendocrine model. In: Bhatnagar AJ (ed) The anterior pituitary gland. Raven Press, New York, pp 97–105

    Google Scholar 

  • Ramirez VD, Kim K, Dluzen D (1985) Progesterone action on the LHRH and the nigrostriatal dopamine neuronal systems: in vitro and in vivo studies. In: Greep RO (ed) Recent progress in hormone research, vol 41. Academic Press, Orlando, pp 421–472

    Google Scholar 

  • Strong R, Moore MA, Hale C, Wessels-Reiker M, Armbrecht HJ, Richardson A (1990) Modulation of tyrosine hydroxylase gene expression in the rat adrenal gland by age and reserpine. Brain Res 525: 126–132

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dluzen, D.E., Kratko, F.T. L-DOPA infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine. J. Neural Transmission 89, 197–207 (1992). https://doi.org/10.1007/BF01250672

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01250672

Keywords

Navigation